Loading clinical trials...
Loading clinical trials...
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Conditions
Interventions
LB1901
Locations
4
United States
Mayo Clinic
Rochester, Minnesota, United States
MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Start Date
September 13, 2021
Primary Completion Date
December 1, 2023
Completion Date
December 1, 2025
Last Updated
October 3, 2023
NCT07523555
NCT07388563
NCT06561048
NCT05679895
NCT04752826
NCT06909877
Lead Sponsor
Legend Biotech USA Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions